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Chemotherapy in non–small cell lung
cancer: An update of an individual
patient data-based meta-analysis
To the Editor:
In the September 2004 issue of the Journal,
Sedrakyan and associates1 reported a sys-
tematic review and meta-analysis of post-
operative chemotherapy versus surgery
alone in non–small cell lung cancer. This
meta-analysis is based on abstracted data
from 15 randomized controlled trials
(RCTs). This included 7200 patients and
builds on results of our individual patient
data-based (IPD) meta-analysis,2 published
in 1995.
The Non–Small Cell Lung Cancer
Collaborative Group, which was respon-
sible for the IPD meta-analysis published
in 1995, welcomes the meta-analysis pro-
vided by Sedrakyan and associates,1
which added summary data from 7 trials
and approximately 5000 patients to infor-
mation from the 1995 meta-analysis.
However, the interpretation of the results
is limited by the absence of trial descrip-
tion and quality evaluation. Furthermore,
the results of any systematic review per-
formed with data extracted from publica-
tions of trials should be viewed with a
degree of caution.3
IPD meta-analyses, which involve the
central collection, validation, and analy-
sis of the original trial data, are the gold
standard of systematic review and have
many advantages over literature-based
approaches. They allow the reviewer to
check the data, ensure the randomization
process was adequate, investigate heter-
ogeneity, and report longer follow-up,
and can limit many biases.4 They also
permit subgroup analysis of patient level
characteristics such as age or tumor
stage. Of course, it is also well docu-
mented that this type of review takes
longer to carry out.
The 1995 meta-analysis included more
than 9000 patients from 52 RCTs and as-
sessed the effect of chemotherapy in 4 dif-
ferent settings.
An updated and extended IPD meta-
analysis is currently under way, and data
collection is ongoing. New agents and tim-
ings have been investigated in all settings.
The update consists of adding trials pub-
lished since the 1995 analyses and addi-
tional follow-up data from trials already
included, and investigating additional out-
comes in certain settings. Seven different
therapeutic questions will be addressed,
and the total number of patients random-
ized has increased to approximately 23,000
patients. The corresponding protocols are
available at the following websites: http://
www.ctu.mrc.ac.uk/download.asp or http://
www.igr.fr / php /index.php?ids_path2.51.
70.127.567.
In a setting equivalent to that described
by Sedrakyan and associates,1 we identi-
fied 22 new RCTs with more than 8000
new patients, bringing the total number of
trials to 38. If we can include these pa-
tients, it would bring the total number of
patients in this comparison alone to more
than 10,500 patients or 23% more patients
than are included in the review by Se-
drakyan and associates.1
Although the meta-analyses by Se-
drakyan and associates1 and a recent sim-
ilar review by Hotta and associates5 are a
valuable resource in the absence of other
evidence, the results should be consid-
ered with caution until they can be com-
pared with the updated IPD meta-analy-
sis. We anticipate that the results of our
IPD meta-analyses will be available in
2006.
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Reply to the Editor:
We support and applaud the efforts of Ms
Burdett and her team in conducting an indi-
vidual patient data-based (IPD) meta-analysis
of postoperative chemotherapy trials. Al-
though there are controversies regarding the
conduct of IPD meta-analyses, such as the
inclusion of data from unpublished studies
and potential investigator bias in terms of
data submitted,1,2 such studies may be par-
ticularly useful in conducting subgroup anal-
yses to identify those patients most likely to
benefit from therapy and the optimal treat-
ment regimen to be used.
The non-IPD nature of our meta-analysis
does not, however, take away from the valid-
ity of the findings that clearly demonstrate a
survival advantage for patients treated with
adjuvant chemotherapy over those treated
with surgery alone.3 This is also underpinned
by a recent presentation on adjuvant UFT
(uracil and tegafur), the oral 5-fluorouracil
derivative, at the 2004 annual meeting of the
American Society of Clinical Oncology. In
this work, individual patient data from 2003
patients recruited to 6 randomized controlled
trials were systematically reviewed. The
overall survival benefit for treated patients is
5.3% (hazard ratio  0.77; P  .011) at 5
years and 7.7% (hazard ratio  0.74; P 
.001) at 7 years. This is similar to our re-
ported survival benefit for UFT. In addition,
continued divergence of the survival curves
over time is similar to those commonly seen
in breast cancer adjuvant trials.4
The authors are correct that since our pub-
lication, further randomized controlled trials
have been presented. The 2 largest and prin-
cipal new studies presented at the 2004 meet-
ing of the American Society of Clinical On-
cology for platinum-based chemotherapy,
however, reported substantial benefits associ-
ated with adjuvant chemotherapy.5,6 Com-
bining the results of these trials with the pre-
vious randomized controlled trials evaluating
platinum-based regimens has demonstrated a
further overall benefit for platinum-based
postoperative chemotherapy (relative risk,
0.86; 95% confidence interval, 0.80-0.93).
Moreover, sensitivity analyses determined
that even if there were unreported or future
studies enrolling more than 2000 patients that
showed a statistically significant 20% higher
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risk of mortality for platinum-based chemo-
therapy (the very unlikely scenario), the over-
all estimate would still significantly favor
chemotherapy.
In the past there have been many in-
stances in which the failure to adapt signifi-
cant advances in treatment has led to delays
in passing on the benefits to the patient in the
clinic. Examples include thrombolytic ther-
apy or beta-blocker therapy after myocardial
infarctions.7,8 These non–IPD-based system-
atic reviews highlighted that each year of
delay may cost thousands of lives worldwide
and were influential for the development of
evidence-based medicine. We believe that
delay in the case of postoperative chemother-
apy may have the same consequences and be
interpreted as reflecting clinician uncertainty
and potentially lead to the design and conduct
of further clinical trials in which the question
has been clearly answered.9,10 As Sir Austin
Bradford Hill pointed out in his presidential
address at the Royal Society of Medicine
(January 14, 1965), “All scientific work is
incomplete—whether it be observational or
experimental. It is liable to be upset or mod-
ified by advancing knowledge. That does not
confer upon us a freedom to ignore the
knowledge we already have, or to postpone
the action that appears to demand at a given
time.” In this regard the evidence is very
strong that adjuvant chemotherapy improves
patient survival postresection. Optimizing
therapy and targeting those patients most
likely to benefit from treatment are clinically
important questions that the IPD study may
address. Further trials in the already studied
population randomizing patients to a “no che-
motherapy” arm are, however, unlikely to
contribute to existing knowledge and are eth-
ically questionable.
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Single-stage repair of extensive
thoracic aortic aneurysms
To the Editor:
I congratulate Dr Kouchoukos and col-
leagues1 for their excellent results with the
single-stage repair technique of extended
thoracic aortic aneurysms. We originally
introduced this technique2 in 1994 with a
limited series of 16 patients and a hospital
mortality of 12.5%. Ten years ago axillary
artery cannulation, branched arterial grafts,
and antegrade cerebral perfusion were not
routinely used. As a consequence, cerebral
ischemia was longer than today, and pa-
tients had to undergo operation with deep
hypothermia and circulatory arrest. In our
first series cerebral ischemia averaged 55.7
minutes. A further consequence of deep
hypothermia was more frequent respiratory
complications than observed today. During
recent years, we also improved our tech-
nique by adding antegrade cerebral perfu-
sion, either through retrograde axillary ar-
tery perfusion or the “aortic arch (or
branch) first” technique, as suggested by
Dr Kouchoukos and colleagues.1 Body
temperature is generally decreased to no
more than 25°C. Our series now includes
approximately 53 patients with an overall
hospital mortality of 9.4%. Among the last
30 patients, hospital mortality was 6.7%;
neurologic and respiratory complications
accounted for 3.3% and 6.7%, respectively.
In regard to the “clamshell” access, we still
use an approach through a limited right
anterior thoracotomy through the third in-
tercostal space and an anterolateral left tho-
racotomy through the fourth intercostal
space with the patient banked 45 degrees
on the right side. In our opinion, this access
gives an easier approach to the aortic root
along with the arch branches and to the
most distal portion of the thoracic aorta.
Reimplantation of lower intercostal arteries
is not a problem in this way. Contrary to
some of Dr Kouchoukos discussants, I
fully agree with the author on the strategy
of the single-stage approach in complex
cases of thoracic aortic aneurysms. This
often is the case in patients who have un-
dergone operation for acute type A aortic
dissection, in whom the aortic valve had
been repaired and the ascending aorta had
been replaced by a tube graft, even though
it was extended in some cases to a proximal
hemiarch. In such acute instances, the Ben-
tall or equivalent techniques will not be
used universally, and the elephant-trunk
technique will be used even less. A com-
mon late observation in such cases is an-
eurysm development in the aortic root, of-
ten associated with valve incompetence,
and distal part of the arch and descending
aorta. Conventionally, the treatment of these
patients would include a repeat sternotomy
with Bentall or valve-sparing procedures,
arch replacement with the elephant-trunk
technique, and followed later by a second
procedure with replacement or endostenting
of the descending portion of the aorta when-
ever possible. Actually, endovascular stent-
ing of the descending aorta is not always a
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